The approval is for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum under Target Segment III (Key Chemical Synthesis Based KSMs/Drug Intermediates).
Aarti Drugs has procured land to expand its existing Metformin Capacity to 3000 TPM in a brownfield expansion. This expansion would be a two-phase expansion program.